Abstract
Purpose: The purpose of the present study was to examine the roles of new proteins DARS2, Reelin, and Encurin in the differentiation of Clear-Cell Renal Cell Carcinoma (RCC) and Papillary Renal Cell Carcinoma (RCC). Clear-cell RCC is the most common malignancy of the kidney, and papillary RCC is the second most common malignant malignancy in this respect. They are neoplasms and show similarity to each other, both histologically and morphologically, in some cases. Differential diagnosis is important because treatment approaches and prognoses are different. Although careful histopathological examination and specific immunohistochemical markers are important for diagnosis, there are no specific antibodies that can be used reliably and the search for biomarkers continues in this regard.
 Materials and Methods: A total of 30 Clear-Cell RCC and 30 Papillary RCC cases were included in the present study. Patients were identified retrospectively by reviewing the hospital database and pathological reports. Pathological data were obtained from hospital medical archives and pathology reports.
 Results: It was found that DARS2, Reelin, and Encurin proteins were significantly higher in papillary RCC when compared to clear-cell RCC.
 Conclusion: It was concluded that DARS2, Reelin, and Encurin proteins may be potential biomarkers for the differentiation of Papillary RCC and Clear-Cell RCC.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
